Compugen Ltd CGEN
Compugen Ltd (Nasdaq: CGEN) is an oncology drug developer. Its lead program, COM701, is in Phase 1 for Relapsed platinum-sensitive ovarian cancer (maintenance, single agent; MAIA-ovarian trial). Its next catalyst on record is COM701: Interim analysis of MAIA-ovarian trial (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: COM701 — Interim analysis of MAIA-ovarian trial (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| COM701 (anti-PVRIG) | Ovarian cancer maintenance (MAIA-ovarian); solid tumors | antibody | Phase 1 |
| GS-0321 (formerly COM503, anti-IL-18BP; licensed to Gilead) | Solid tumors (Phase 1 run by Compugen) | antibody | Phase 1 |
| COM902 (anti-TIGIT) | Solid tumors | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.